BioSpace News Archive

Machavert obtains worldwide exclusive license to small molecule RAL GTPase inhibitors to treat KRAS cancers

Nanospectra Biosciences, Inc. announced publication of first in human data of the company’s AuroLase® Therapy for the focal ablation of prostate tissue.

Ionis Pharmaceuticals, Inc. announced that GSK exercised its option to license Ionis’ antisense medicines for people with chronic hepatitis B virus infection following positive Phase 2 results.

Castle Biosciences, Inc. announced that Derek Maetzold, President and Chief Executive Officer, is scheduled to present a company overview at the Baird 2019 Global Healthcare Conference in New York City on Wednesday, September 4, 2019, at 2:00 p.m. Eastern time.

Viela Bio announced that the U.S. Food and Drug Administration has accepted for review its Biologics License Application for inebilizumab, an investigational anti-CD19 monoclonal antibody, for the treatment of patients with neuromyelitis optica spectrum disorder — a rare autoimmune disease characterized by unpredictable attacks that often lead to severe, irreparable disability including blindness and paralysis.

Interface Fluidics is a Calgary based laboratory service company with a nanotechnology platform for optimizing oil production and visualizing fluid-fluid interactions, through rapid chemical testing at reservoir temperature and pressure.

AstraZeneca announced that the US Food and Drug Administration has granted Fast Track designation for the development of FARXIGA to delay the progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease.

BiomX Ltd. announced completion of construction of a new state-of-the-art manufacturing facility.

ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has added Dr. Andre Strydom to its scientific advisory board.

Navidea Biopharmaceuticals, Inc. announced receipt of the Notice of Award from the National Heart, Lung, and Blood Institute of the National Institutes of Health for its Small Business Technology Transfer Phase 1 grant application submitted in collaboration with the University of Alabama at Birmingham, titled “Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques.” The grant award number is R41HL147640 and the award amount is $225,000.